Latham Group holds a dominant 50% share of the North American fiberglass pool market and benefits from stable recurring revenues. The company has achieved double-digit revenue growth through acquisitions, geographic expansion, and price increases, despite some short-term profit pressure from investments in growth. Management has raised its full-year revenue guidance to $600–$620 million and EBITDA to $110–$120 million, signaling confidence in continued operational momentum. The stock trades at a discount compared to peers, with upcoming Q3 results expected to show further gains in revenue and profit.
Latham Group's market context is provided with a breadth of 134 priced Consumer Cyclical-sector US stocks on Pluang, where only 13 rose and 119 fell as of Oct 23, 2026 21:01 WIB. For readers following this sector, notable movers include JMKE at USD 17.05 with a 1-day change of -3.62% and a typical hold time on Pluang of 8 days, LULU at USD 100.38 with a 1-day change of -3.54% and a Pluang order activity of 5% Sell / 95% Buy with a typical hold time of 107 days, and SGHC at USD 10.95 with a 1-day change of -3.52% and a typical hold time of 8 days.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
